The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021. The drug candidate Dapagliflozin and metformin extended release is included in 17 formulations out of 20 for which price fixation is applied. Dapagliflozin was patented by AstraZeneca and there are sixteen USA patents protecting this drug and one Paragraph IV challenge.
- Read more about NPPA fixed retail prices of 20 formulations
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/nppa-fixed-retail-prices-of-20-formulations
No comments:
Post a Comment